Isatuximab - Immunogen/Sanofi

Drug Profile

Isatuximab - Immunogen/Sanofi

Alternative Names: Anti-CD38 monoclonal antibody - Sanofi; hu38SB19; SAR-650984

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Developer Huntsman Cancer Institute; Sanofi
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase II T cell lymphoma
  • Phase I/II Non-small cell lung cancer; Prostate cancer
  • Discontinued Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 07 Feb 2018 Sanofi and Genentech enter a research collaboration to study atezolizumab in combination with isatuximab in Solid tumours
  • 07 Feb 2018 Sanofi announces intention to submit NDA to US FDA for Multiple myeloma (Combination therapy, Second-line therapy or greater) in fourth quarter of 2018
  • 07 Feb 2018 Sanofi announces intention to submit NDA to US FDA for Multiple myeloma (First line therapy) in 2021
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top